CDK12 is known to play a role in about 7% of metastatic prostate cancers and about 3% of tubo-ovarian high-grade serous cancers. It has not been shown to be inactivated in other cancer types.

A new study from the University of Michigan sheds light on the genetic roots of a deadly form of ovarian cancer and points toward a potential new treatment strategy. The research, published in the ...

Researchers previously found loss of the CDK12 gene in about 7% of patients with metastatic prostate cancer, suggesting this alteration may be linked to a more-aggressive form of the disease.

"CDK12 is a recently identified gene that controls the expression of genes required for DNA repair, but its detailed mechanism and function are just beginning to be explored," says first author ...

Researchers previously found loss of the CDK12 gene in about 7% of patients with metastatic prostate cancer, suggesting this alteration may be linked to a more-aggressive form of the disease.

Researchers previously found loss of the CDK12 gene in about 7% of patients with metastatic prostate cancer, suggesting the alteration may be linked to a more aggressive form of the disease.. That ...

Based on the study findings, CDK12 is a tumor suppressor gene, and YJ1206, a CDK12/13 degrader, is a potential therapeutic candidate for preclinical models of advanced prostate cancer.

A potential new treatment for an aggressive form of prostate cancer has shown promise in lab tests. American scientists have shown how a gene alteration drives the disease and have also discovered ...

In two new papers, both published in Cell Reports Medicine, researchers from the University of Michigan Rogel Cancer Center describe the mechanisms of how alterations in the CDK12 gene drive ...

Researchers had previously found loss of the CDK12 gene in about 7% of patients with metastatic prostate cancer, suggesting this alteration may be linked to a more-aggressive form of the disease.